Plain-English translation of NCT06756217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging scan called 68Ga-grazytracer PET/CT to see if it can help doctors figure out early whether immunotherapy is working for your lung cancer. You would receive standard immunotherapy treatment (pembrolizumab combined with chemotherapy) over 9 weeks, and get special imaging scans at the start and partway through to see how your cancer is responding. The goal is to give doctors a better tool to predict which patients will benefit most from this treatment before surgery.
Right now, doctors have a hard time knowing early on whether immunotherapy is actually working against a patient's cancer without waiting a long time or doing invasive tests. This trial aims to see if the new imaging scan can give doctors faster, clearer answers about treatment success so they can make better decisions about surgery and care.
You likely qualify if…
You likely don't qualify if…
You would receive immunotherapy treatment (pembrolizumab plus chemotherapy) as injections every 3 weeks for 3 cycles (about 9 weeks total). You would have imaging scans (PET/CT) at the beginning of the study and again before your third cycle of treatment to see how your cancer is responding. After completing the treatment, you would go on to have surgery as planned, and doctors would compare what the imaging showed with what they find during surgery.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Sponsor
Ruijin Hospital
Enrollment target
~40 participants
Started
December 2024
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hecheng Li, MD, PHD
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.